TY - JOUR
T1 - Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis
AU - Alffenaar, Jan Willem C.
AU - Gumbo, Tawanda
AU - Dooley, Kelly E.
AU - Peloquin, Charles A.
AU - McIlleron, Helen
AU - Zagorski, Andre
AU - Cirillo, Daniela M.
AU - Heysell, Scott K.
AU - Silva, Denise Rossato
AU - Migliori, Giovanni Battista
N1 - Publisher Copyright:
© The Author(s) 2019.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/4/15
Y1 - 2020/4/15
N2 - Tuberculosis (TB) elimination requires innovative approaches. The new Global Tuberculosis Network (GTN) aims to conduct research on key unmet therapeutic and diagnostic needs in the field of TB elimination using multidisciplinary, multisectorial approaches. The TB Pharmacology section within the new GTN aims to detect and study the current knowledge gaps, test potential solutions using human pharmacokinetics informed through preclinical infection systems, and return those findings to the bedside. Moreover, this approach would allow prospective identification and validation of optimal shorter therapeutic durations with new regimens. Optimized treatment using available and repurposed drugs may have an increased impact when prioritizing a personcentered approach and acknowledge the importance of age, gender, comorbidities, and both social and programmatic environments. In this viewpoint article, we present an in-depth discussion on how TB pharmacology and the related strategies will contribute to TB elimination.
AB - Tuberculosis (TB) elimination requires innovative approaches. The new Global Tuberculosis Network (GTN) aims to conduct research on key unmet therapeutic and diagnostic needs in the field of TB elimination using multidisciplinary, multisectorial approaches. The TB Pharmacology section within the new GTN aims to detect and study the current knowledge gaps, test potential solutions using human pharmacokinetics informed through preclinical infection systems, and return those findings to the bedside. Moreover, this approach would allow prospective identification and validation of optimal shorter therapeutic durations with new regimens. Optimized treatment using available and repurposed drugs may have an increased impact when prioritizing a personcentered approach and acknowledge the importance of age, gender, comorbidities, and both social and programmatic environments. In this viewpoint article, we present an in-depth discussion on how TB pharmacology and the related strategies will contribute to TB elimination.
KW - Drug resistance
KW - Pharmacodynamics
KW - Pharmacokinetics
KW - Therapeutic drug monitoring
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85083539777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083539777&partnerID=8YFLogxK
U2 - 10.1093/cid/ciz942
DO - 10.1093/cid/ciz942
M3 - Review article
C2 - 31560376
AN - SCOPUS:85083539777
VL - 70
SP - 1734
EP - 1780
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 8
ER -